Opendata, web and dolomites


A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells

Total Cost €


EC-Contrib. €






 NeoCellBank project word cloud

Explore the words cloud of the NeoCellBank project. It provides you a very rough idea of what is the project "NeoCellBank" about.

palliative    rely    diseases    human    people    veterinary    altered    oa    19    cells    euros    mechanism    tissue    humans    solutions    abundant    status    multiple    foresee    earn    shared    finalise    burden    stronger    vetbiobank    individual    animals    donor    introducing    lower    market    source    accessible    advantages    million    inflammation    anti    mainly    hire    immunogenicity    chronic    medicine    profits    26    experiencing    society    osteoarthritis    solution    20    biological    limited    context    ageing    accelerator    mature    stem    adult    recipients    commercial    incurring    therapies    expensive    hold    pathology    joint    treatments    pay    good    appears    industrialization    reaching    limits    lifestyle    cell    involve    lengthy    nsaids    estimating    material    15    invasive    inflammatory    pets    endogenous    pharmacological    therapy    unrestricted    incidence    age    underlying    profile    allogeneic    regenerative    reverse    investment    effort    disability    economic    pro    completion    mostly    neonatal    alternative    stage    off    regeneration    return    amplification    symptoms    revolutionize    overcome    autologous    sedentary    disrupt   

Project "NeoCellBank" data sheet

The following table provides information about the project.


Organization address
postcode: 69280
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VETBIOBANK SAS FR (MARCY-L'ETOILE) coordinator 50˙000.00


 Project objective

Society is experiencing a rise in chronic inflammatory diseases, mostly due to ageing, and sedentary lifestyle. Osteoarthritis (OA) is one of the leading inflammatory diseases, affecting both humans (incidence 15%) and pets (20%), incurring disability and large economic burden. Current pharmacological treatments for OA involve palliative therapies (NSAIDs) that work on the symptoms, becoming lengthy and expensive with multiple side effects. In this context, regenerative medicine based on stem cells appears as a good alternative, as they reverse the pro-inflammatory status of the joint and promote endogenous tissue regeneration. However, current solutions for OA mainly rely on autologous adult stem cells, obtained through invasive procedures and which hold biological properties altered by donor age and underlying inflammation. Allogeneic adult cells could be used in any individual, but a limited amplification potential limits the number of recipients. In response, we aim to revolutionize the field of regenerative medicine by introducing a unique cell therapy based on neonatal stem cells. These cells have many advantages over adult cells: source material is accessible & abundant, cells show stronger anti-inflammatory properties, and lower immunogenicity profile which allows for unrestricted allogeneic use. The main goal of our project is to finalise industrialization and bring to market our reliable cell-based solution for OA. In Phase 1 we will define the technical and commercial steps to overcome before reaching mature stage. Upon completion of this project, we foresee our product to disrupt the veterinary market of inflammatory diseases. Moreover, since the pathology mechanism for OA is shared between animals and humans, our product could work as an accelerator for human applications. Importantly, the effort will pay off for Vetbiobank, estimating to earn €26 million profits, hire 19 people and reach a Return of Investment of 4.2 Euros after 5 years in the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEOCELLBANK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEOCELLBANK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HAC (2019)


Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More